![]() |
Sign Up! | Tags | Domains | Statistics | Options | Advanced Search |
aidsmap.com » aidsmap.com news feed : aidsmap news - Nov 16, 2008
Once-a-day dosing of the newly-licensed non-nucleoside (NNRTI) drug etravirine (TMC125, Intelence) should be sufficient to suppress HIV in patients without NNRTI resistance, the Ninth Congress on Drug Therapy in HIV …
Also tagged: conference news
aidsmap.com » aidsmap.com news feed : aidsmap news - Nov 16, 2008
Once-a-day dosing of the newly-licensed non-nucleoside (NNRTI) drug etravirine (TMC125, Intelence) should be sufficient to suppress HIV in patients without NNRTI resistance, the Ninth Congress on Drug Therapy in HIV …
Also tagged: conference news
aidsmap.com » aidsmap.com news feed : aidsmap news - Nov 13, 2008
Nearly 20% of patients in an HV treatment programme in Kenya have suffered major interactions between their HIV drugs and other prescribed medicines, a study has found. In half of these cases the result of the …
Also tagged: africa news, conference news
aidsmap.com » aidsmap.com news feed : aidsmap news - Nov 2, 2008
HIV treatment can cut the risk of death in severely immune suppressed patients who have cryptococcal meningitis and HIV, researchers from Botswana report in the October 1st edition of the Journal of Acquired Immune …
Also tagged: palliative care news
aidsmap.com » aidsmap.com news feed : aidsmap news - Oct 31, 2008
The currently recommended dosage of rifampicin for children may be too low according to a fairly large pharmacokinetic study presented at the 39th Union World Conference on Lung Health held in Paris.
Also tagged: conference news, tuberculosis news, children and hiv news
aidsmap.com » aidsmap.com news feed : aidsmap news - Aug 15, 2008
A new 100 mg tablet formulation of the protease inhibitor ritonavir (Norvir) appears to be equivalent to the current soft-gel capsule formulation in terms of side-effects and boosting potential, according to data …
Also tagged: conference news, mexico 2008, new drugs news, side effects news